Real World Evidence in Alopecia Areata: Current Management, Emerging Therapies and Future Challenges – A Narrative Review

    June 2026 in “ Journal of Inflammation Research ”
    Fatimah Khoda, Anne Chandidzura, Rodney Sinclair … Matthew Harries
    Studysummary This narrative review discusses how new targeted therapies, like biologics and small molecules, are transforming alopecia areata treatment and highlights the establishment of the GRASS-UK/GRASS-International network to investigate the long-term safety and effectiveness of these new treatments.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on badbir.org →
    Discuss this study in the Community →

    Research cited in this study 74

    1. Ritlecitinib Efficacy in Adolescents With Alopecia Areata: A Real-World Experience International Journal of Dermatology · 2026
    2. Ritlecitinib in Alopecia Areata: A 24-Week Real-World Experience Contrasting JAK Inhibitor-Naïve and JAK Inhibitor-Experienced Patients The Journal of Dermatology · 2025
    3. Combined Low Dose Oral Minoxidil and Immunomodulator Efficacy and Safety in Alopecia Areata: A Systematic Review International Journal of Dermatology · 2025
    4. Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase 1/2 Inhibitor, in Adults with Alopecia Areata: Results from the THRIVE-AA2 Phase 3, Randomized, Double-Blind, Controlled Trial Journal of the American Academy of Dermatology · 2025
    5. Effectiveness And Safety Of Baricitinib In Alopecia Areata: A Prospective Cohort Study Journal of Dermatological Treatment · 2025
    6. British Association of Dermatologists Living Guideline for Managing People with Alopecia Areata 2025 British Journal of Dermatology · 2025
    7. Predictive Factors of Response and Real-World Experience of Baricitinib on Alopecia Areata: A Single Tertiary Center Study on a 72 Patients' Cohort International Journal of Dermatology · 2025
    8. Defining a Therapeutic Window of Opportunity in Alopecia Areata: Predictors of Early Response to Baricitinib Journal of Clinical Medicine · 2025
    9. Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata Dermatology and Therapy · 2025
    10. Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement Australasian Journal of Dermatology · 2025
    11. Effectiveness and Safety of Baricitinib in Severe Alopecia Areata: 48-Week Results Journal of the European Academy of Dermatology and Venereology · 2025
    12. Duration of Current Alopecia Areata Episode Predicts the Effectiveness of Baricitinib in Japanese Patients: A Single-Center Retrospective Study Journal of Dermatological Treatment · 2025
    13. Safety of Oral JAK Inhibitors in Treating Alopecia Areata: A Systematic Review and Network Meta-Analysis Frontiers in Pharmacology · 2025
    14. The Emotional Impact of Alopecia and Role of Psychological Interventions in Supporting Patients With Hair Loss Clinical and Experimental Dermatology · 2025
    15. Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS) Database: A Real-World Pharmacovigilance Study The Journal of Dermatology · 2025
    16. Real-World Assessment of Ritlecitinib in Patients with Severe Alopecia Areata: A 24-Week Multicentre Retrospective Study Clinical and Experimental Dermatology · 2025
    17. Long-Term Real-World Outcomes of Baricitinib in Severe Alopecia Areata: A 104-Week Retrospective Analysis From a Single Institute The Journal of Dermatology · 2025
    18. Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020–2023 Dermatology and Therapy · 2025
    19. Local Corticosteroids for Alopecia Areata: A Narrative Review Dermatology and Therapy · 2025
    20. Efficacy and Safety of Long-Term Azathioprine Therapy for Severe Alopecia Areata: A 10-Year Cohort Study Journal of Cosmetic Dermatology · 2025
    21. Real-World Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients Acta Dermato Venereologica · 2025
    22. The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta-Analysis Study Journal of Cosmetic Dermatology · 2025
    23. Real-Life Effectiveness and Safety of Baricitinib in Adults with Alopecia Areata: A Multicenter Study Journal of the European Academy of Dermatology and Venereology · 2025
    24. Effectiveness of Baricitinib in Alopecia Areata Patients With a Current Episode Lasting Longer Than 8 Years: An Italian Multicenter Real-Life Experience in the Lazio Region International Journal of Dermatology · 2025
    25. Most Men Choose Eyebrows Over Scalp Hair: Response to Mostaghimi et al., 'Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA2 Trial of Deuruxolitinib in Adult Patients with Alopecia Areata' Journal of the American Academy of Dermatology · 2025
    26. Patterns of Clinical Response in Patients With Alopecia Areata Treated With Ritlecitinib in the Allegro Clinical Development Programme Journal of the European Academy of Dermatology and Venereology · 2025
    27. Long-Term Safety and Efficacy of Ritlecitinib in Adults and Adolescents with Alopecia Areata and at Least 25% Scalp Hair Loss: Results from the ALLEGRO-LT Phase 3, Open-Label Study Journal of the European Academy of Dermatology and Venereology · 2025
    28. Baricitinib for the Treatment of Severe Alopecia Areata: Results from a 52-Week Multicenter Retrospective Real-World Study Journal of Dermatological Treatment · 2025
    29. Clinical Efficacy and Safety of Baricitinib in Patients With Alopecia Areata in Korea Annals of Dermatology · 2025
    30. STRIAA (Severity Trichoscopy Index Alopecia Areata): Validation Of A Novel Trichoscopic Tool For Evaluation Of Alopecia Areata Dermatology and Therapy · 2024
    31. Prescribing Patterns Amongst UK Dermatologists for the Treatment of Alopecia Areata, Female Pattern Hair Loss, and Frontal Fibrosing Alopecia JEADV Clinical Practice · 2024
    32. Alopecia Areata Treatment Patterns and Satisfaction: Results of a Real-World Cross-Sectional Survey in Europe Dermatology and Therapy · 2024
    33. Real-Life Effectiveness and Safety of Baricitinib in Patients with Severe Alopecia Areata: A 24-Week Italian Study Journal of the European Academy of Dermatology and Venereology · 2024
    34. Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata JAMA Dermatology · 2024
    35. Lifetime Incidence and Healthcare Disparities in Alopecia Areata: A UK Population-Based Cohort Study British Journal of Dermatology · 2024
    36. A Retrospective Analysis of Disease Epidemiology, Comorbidities, Treatment Patterns, and Healthcare Resource Utilization of Alopecia Areata in the United Arab Emirates Using Claims Database The Journal of Dermatology · 2024
    37. Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1) Journal of the American Academy of Dermatology · 2024
    38. Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis with Focus on Safety Dermatology Practical & Conceptual · 2024
    39. Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions: Results from a Survey in Five European Countries Dermatology and therapy · 2024
    40. Vibration Assisted Analgesia During Intralesional Corticosteroid Therapy for Alopecia Skin health and disease · 2024
    41. Degree of Alignment Between Japanese Patients and Physicians on Alopecia Areata Disease Severity and Treatment Satisfaction: A Real-World Survey Dermatology and therapy · 2023
    42. Physician and Patient-Reported Severity and Quality of Life Impact of Alopecia Areata: Results from a Real-World Survey in Five European Countries Dermatology and therapy · 2023
    43. Establishing The Financial Burden Of Alopecia Areata And Its Predictors Skin health and disease · 2023
    44. Effectiveness and Safety of Baricitinib in Patients With Severe Alopecia Areata: A 36-Week Multicenter Real-World Experience Journal of Dermatological Treatment · 2023
    45. Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials British Journal of Dermatology · 2023
    46. Economic Burden of Alopecia Areata: A Study of Direct and Indirect Cost in Japan Using Real-World Data Journal of dermatology · 2023
    47. Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database Dermatology and therapy · 2023
    48. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    49. Prevalence, Comorbidities, and Treatment Patterns of Japanese Patients with Alopecia Areata: A Descriptive Study Using Japan Medical Data Center Claims Database The Journal of Dermatology · 2022
    50. Treatment Patterns and Treatment Satisfaction Among Adults With Alopecia Areata in the United States Advances in Therapy · 2022
    51. Signposts to the Promised Land in Alopecia Areata Journal of Investigative Dermatology · 2022
    52. Healthcare Utilization And Costs Among US Adolescents With Alopecia Areata Journal of health economics and outcomes research · 2022
    53. The Associated Burden of Mental Health Conditions in Alopecia Areata: A Population-Based Study in UK Primary Care British Journal of Dermatology · 2022
    54. Epidemiology, Management, and the Associated Burden of Mental Health Illness, Atopic and Autoimmune Conditions, and Common Infections in Alopecia Areata: Protocol for an Observational Study Series BMJ Open · 2021
    55. The Epidemiology of Alopecia Areata: A Population-Based Cohort Study in UK Primary Care British Journal of Dermatology · 2021
    56. A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
    57. Utility of Azathioprine, Methotrexate, and Cyclosporine as Steroid-Sparing Agents in Chronic Alopecia Areata: A Retrospective Study of Continuation Rates in 138 Patients JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2020
    58. The Alopecia Areata Investigator Global Assessment Scale: A Measure for Evaluating Clinically Meaningful Success in Clinical Trials British Journal of Dermatology · 2020
    59. Efficacy of Different Concentrations of Intralesional Triamcinolone Acetonide for Alopecia Areata: A Systematic Review and Meta-Analysis Journal of the American Academy of Dermatology · 2019
    60. Benefit and Risk Profile of Tofacitinib for the Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis Journal of the European Academy of Dermatology and Venereology · 2019
    61. Weekly Azathioprine Pulse Versus Betamethasone Oral Mini-Pulse in the Treatment of Moderate-to-Severe Alopecia Areata Indian Journal of Dermatology · 2019
    62. Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata JAMA Dermatology · 2018
    63. Hair Follicle Immune Privilege Revisited: The Key to Alopecia Areata Management ˜The œjournal of investigative dermatology. Symposium proceedings/˜The œJournal of investigative dermatology symposium proceedings · 2017
    64. The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm Advances in Therapy · 2017
    65. The Changing Landscape of Alopecia Areata: The Translational Landscape Advances in Therapy · 2017
    66. A Mixed Methods Survey of Social Anxiety, Anxiety, Depression, and Wig Use in Alopecia BMJ open · 2017
    67. Pulse Corticosteroid Therapy With Oral Dexamethasone for the Treatment of Adult Alopecia Totalis and Universalis Journal of the American Academy of Dermatology · 2016
    68. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    69. The Role of Hair Follicle Immune Privilege Collapse in Alopecia Areata: Status and Perspectives Journal of Investigative Dermatology Symposium Proceedings · 2013
    70. Clobetasol Propionate, 0.05%, vs Hydrocortisone, 1%, for Alopecia Areata in Children JAMA dermatology · 2013
    71. British Association of Dermatologists’ Guidelines for the Management of Alopecia Areata 2012 British Journal of Dermatology · 2012
    72. Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity Nature · 2010
    73. A Comparison of the Efficacy, Relapse Rate, and Side Effects Among Three Modalities of Systemic Corticosteroid Therapy for Alopecia Areata Dermatology · 2006
    74. Guidelines for the Management of Alopecia Areata British Journal of Dermatology · 2003